Benzinga | May 17, 2021 07:16AM EDT

Pieris Pharmaceuticals Q1 EPS $(0.07) Beats $(0.17) Estimate, Sales $15.63M Beat $6.47M Estimate

Pieris Pharmaceuticals (NASDAQ:PIRS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.17) by 58.82 percent. This is unchanged from the same period last year. The company reported quarterly sales of $15.63 million which beat the analyst consensus estimate of $6.47 million by 141.62 percent. This is a 17.89 percent increase over sales of $13.26 million the same period last year.